Potential benefits of phytochemicals against Alzheimer's disease

Research output: Contribution to journalArticlepeer-review

52 Citations (Scopus)
54 Downloads (Pure)


Our current therapeutic drugs for Alzheimer's disease are predominantly derived from the alkaloid class of plant phytochemicals. These drugs, such as galantamine and rivastigmine, attenuate the decline in the cholinergic system but, as the alkaloids occupy the most dangerous end of the phytochemical spectrum (indeed they function as feeding deterrents and poisons to other organisms within the plant itself), they are often associated with unpleasant side effects. In addition, these cholinesterase inhibiting alkaloids target only one system in a disorder, which is typified by multifactorial deficits. The present paper will look at the more benign terpene (such as Ginkgo biloba, Ginseng, Melissa officinalis (lemon balm) and Salvia lavandulaefolia (sage)) and phenolic (such as resveratrol) phytochemicals; arguing that they offer a safer alternative and that, as well as demonstrating efficacy in cholinesterase inhibition, these phytochemicals are able to target other salient systems such as cerebral blood flow, free radical scavenging, anti-inflammation, inhibition of amyloid-β neurotoxicity, glucoregulation and interaction with other neurotransmitters (such as γ-aminobutyric acid) and signalling pathways (e.g. via kinase enzymes).
Original languageEnglish
Pages (from-to)106-112
JournalProceedings of the Nutrition Society
Issue number2
Early online date1 Feb 2017
Publication statusPublished - 1 May 2017


Dive into the research topics of 'Potential benefits of phytochemicals against Alzheimer's disease'. Together they form a unique fingerprint.

Cite this